Sign inJoin waitlistJoin the waitlist

David Gershenson

Professor and Chair of Gynecologic Oncology and Reproductive Medicine · University of Texas M D Anderson Cancer Center

Credentials: · · · ·

History

Gynecologic Oncology and Reproductive Medicine Department · University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

Gynecologic Oncology
U.T. M. D. Anderson Hospital and Tumor Institute
1977–1979
Obstetrics and Gynecology
Yale-New Haven Hospital
1972–1975
University of Iowa Hospitals and Clinics
1971–1972
Vanderbilt University School of Medicine
1967–1971

Research

Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer
New England Journal of Medicine · 1999 · 1,758 citations
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma
Nature Medicine · 2006 · 1,063 citations
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG)…
Journal of Clinical Oncology · 2004 · 785 citations

Anil Sood
78 papers
JW
J. Wharton
77 papers
TB
Thomas Burke
77 papers
ES
Elvio Silva
73 papers
Larry Copeland
71 papers · 2 as a fellow
CL
Charles Levenback
63 papers · 2 as a fellow
Karen Lu
59 papers · 7 as a fellow
JK
John Kavanagh
54 papers
RC
Robert Coleman
52 papers · 1 as a fellow
MD
Michael Deavers
49 papers
Anais Malpica
45 papers
JW
Judith Wolf
40 papers · 6 as a fellow

Grants

The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer
National Cancer Institute · P50
Project lead · $2.1M · University of Tx Md Anderson Can Ctr
2008–2017
Training of Academic Gynecologic Oncologists
National Cancer Institute · T32
Contact PI · $1.7M · University of Tx Md Anderson Can Ctr
2005–2010

Clinical trials

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Principal investigator · Completed · Phase 2, Phase 3
National Cancer Institute (NCI)
2014–2025
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
Principal investigator · Active not recruiting · Phase 3
National Cancer Institute (NCI)
2010–2027
Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors
Principal investigator · Recruiting
M.D. Anderson Cancer Center
2006–2035
Gleevec Study for Patients With Ovarian Cancer
Principal investigator · Completed · Phase 2
M.D. Anderson Cancer Center
2002–2012